IBI3002 Safety Study in Healthy and Asthmatic Participants Underway
A randomized, double-blind, placebo-controlled study is evaluating the safety and tolerability of IBI3002 in healthy participants and asthma patients.
Company
Pharmaceutical intelligence for IBI Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.